Selected recent publications:

• Sasaki K, Kohanbash G, Hoji A, Ueda R, McDonald HA, Reinhart TA, Martinson J, Lotze MT, Marincola FM, Wang E, Fujita M, Okada H.  miR-17-92 expression in differentiated T cells - implications for cancer immunotherapy.  Journal of Translational Medicine.  2010 Feb 18;8:17.
• Okada H, Kohanbash G, Lotze MT.  MicroRNAs in immune regulation-Opportunities for cancer immunotherapy.  International Journal of Biochemistry and Cell Biology.  Epub 2010 Feb 6.
• Tang D, Kang R, Zeh HJ 3rd, Lotze MT.  High-mobility group box 1 and cancer.  Biochimica et Biophysica Acta.  2010 Jan-Feb;1799(1-2):131-40.
• Chavez AR, Buchser W, Basse PH, Liang X, Appleman LJ, Maranchie JK, Zeh H, de Vera ME, Lotze MT.  Pharmacologic administration of interleukin-2.  Annals of the New York Academy of Science.  2009 Dec;1182:14-27.
• Livesey KM, Tang D, Zeh HJ, Lotze MT.  Autophagy inhibition in combination cancer treatment.  Current Opinion in Investigative Drugs.  2009 Dec;10(12):1269-79.  Review.
• Kang R, Tang D, Schapiro NE, Livesey KM, Farkas A, Loughran P, Bierhaus A, Lotze MT, Zeh HJ.  The receptor for advanced glycation end products (RAGE) sustains autophagy and limits apoptosis, promoting pancreatic tumor cell survival.  Cell Death and Differentiation.  2010 Apr;17(4):666-76.  Epub 2009 Oct 16.
• Lotfi R, Herzog GI, DeMarco RA, Beer-Stolz D, Lee JJ, Rubartelli A, Schrezenmeier H, Lotze MT.  Eosinophils oxidize damage-associated molecular pattern molecules derived from stressed cells.  Journal of Immunology.  2009 Oct 15;183(8):5023-31.  Epub 2009 Sep 30.
• Liang X, Chavez AR, Schapiro NE, Loughran P, Thorne SH, Amoscato AA, Zeh HJ, Beer-Stolz D, Lotze MT, de Vera ME.  Ethyl pyruvate administration inhibits hepatic tumor growth.  Journal Leukocyte Biology.  2009 Sep;86(3):599-607.
• Ueda R, Kohanbash G, Sasaki K, Fujita M, Zhu X, Kastenhuber ER, McDonald HA, Potter DM, Hamilton RL, Lotze MT, Khan SA, Sobol RW, Okada H.  Dicer-regulated microRNAs 222 and 339 promote resistance of cancer cells to cytotoxic T-lymphocytes by down-regulation of ICAM-1.  Proceedings of the National Academy of Science U S A.  2009 Jun 30;106(26):10746-51.  Epub 2009 Jun 11.
• Pan P, Cardinal J, Dhupar R, Rosengart MR, Lotze MT, Geller DA, Billiar TR, Tsung A.  Low-dose cisplatin administration in murine cecal ligation and puncture prevents the systemic release of HMGB1 and attenuates lethality.  Journal of Leukocyte Biology.  2009 Sep;86(3):625-32.
• Davé SH, Tilstra JS, Matsuoka K, Li F, DeMarco RA, Beer-Stolz D, Sepulveda AR, Fink MP, Lotze MT, Plevy SE.  Ethyl pyruvate decreases HMGB1 release and ameliorates murine colitis.  Journal of Leukocyte Biology.  2009 Sep;86(3):633-43.  Epub 2009 May 19.
• Lotfi R, Schrezenmeier H, Lotze MT.  Immunotherapy for cancer: promoting innate immunity.  Frontiers in Bioscience.  2009 Jan 1;14:818-32.
• Tang D, Kang R, Xiao W, Zhang H, Lotze MT, Wang H, Xiao X.  Quercetin prevents LPS-induced high-mobility group box 1 release and proinflammatory function.  American Journal of Respiratory Cell and Molecular Biology.  2009 Dec;41(6):651-60.  Epub 2009 Mar 5.
• Romo de Vivar Chavez A, de Vera ME, Liang X, Lotze MT. The biology of interleukin-2 efficacy in the treatment of patients with renal cell carcinoma. Medical Oncology. 2009;26 Suppl 1:3-12. Epub 2009 Jan 16.
• Sparvero LJ, Asafu-Adjei D, Kang R, Tang D, Amin N, Im J, Rutledge R, Lin B, Amoscato AA, Zeh HJ, Lotze MT.  RAGE (Receptor for Advanced Glycation Endproducts), RAGE Ligands, and their role in Cancer and Inflammation.  Journal of Translational Medicine.  2009 Mar 17;7(1):17.
  
• Lotfi R, Schrezenmeier H, Lotze MT.  Immunotherapy for cancer: promoting innate immunity.  Frontiers in Bioscience.  2009 Jan 1;14:818-32.
  
• Tang D, Kang R, Xiao W, Zhang H, Lotze MT, Wang H, Xiao X.  Quercetin Prevents Lipopolysaccharide-induced HMGB1 Release and Proinflammatory Function.  American Journal of Respiratory Cell and Molecular Biology.  2009 Mar 5.
  
• Moschos SJ, Mandic M, Kirkwood JM, Storkus WJ, Lotze MT.  Focus on FOCIS: interleukin 2 treatment associated autoimmunity.  Clinical Immunology.  2008 May;127(2):123-9.  Review.
  
• Vakkila J, Demarco RA, Lotze MT.  Coordinate NF-kappaB and STAT1 activation promotes development of myeloid type 1 dendritic cells.  Scandinavian Journal of Immunology.  2008 Mar;67(3):260-9.
  
• Lotfi R, Lotze MT.  Eosinophils induce DC maturation, regulating immunity.  Journal of Leukocyte Biology.  2008 Mar;83(3):456-60.  Epub 2007 Nov 8.
  
• Ostberg T, Wähämaa H, Palmblad K, Ito N, Stridh P, Shoshan M, Lotze MT, Harris HE, Andersson U.  Oxaliplatin retains HMGB1 intranuclearly and ameliorates collagen type II-induced arthritis.  Arthritis Research and Therapy. 2008;10(1):R1.  Epub 2008 Jan 7.
  
• Lotze MT, Zeh HJ, Rubartelli A, Sparvero LJ, Amoscato AA, Washburn NR, Devera ME, Liang X, Tör M, Billiar T.  The grateful dead: damage-associated molecular pattern molecules and reduction/oxidation regulate immunity.  Immunological Reviews.  2007 Dec;220:60-81.  Review.
• Zetterström CK, Jiang W, Wähämaa H, Ostberg T, Aveberger AC, Schierbeck H, Lotze MT, Andersson U, Pisetsky DS, Erlandsson Harris H.  Pivotal advance: inhibition of HMGB1 nuclear translocation as a mechanism for the anti-rheumatic effects of gold sodium thiomalate.  Journal of Leukocyte Biology.  2008 Jan;83(1):31-8.  Epub 2007 Oct 3.
  
• Hikawa H, Lotze MT, Rosenblum WD.  Induction of peripheral tolerance by local delivery of dendritic cell progenitors to cardiac allografts in a murine heterotopic heart transplantation model.  General Thoracic and Cardiovascular Surgery.  2007 Aug;55(8):307-14.
  
• Rubartelli A, Lotze MT.  Inside, outside, upside down: damage-associated molecular-pattern molecules (DAMPs) and redox.  Trends in Immunology.  2007 Oct;28(10):429-36.  Epub 2007 Sep 12.
  
• Del Vecchio M, Bajetta E, Canova S, Lotze MT, Wesa A, Parmiani G, Anichini A.  Interleukin-12: biological properties and clinical application.  Clinical Cancer Research.  2007 Aug 15;13(16):4677-85.  Review.
  
• Dong Xda E, Ito N, Lotze MT, Demarco RA, Popovic P, Shand SH, Watkins S, Winikoff S, Brown CK, Bartlett DL, Zeh HJ 3rd.  High mobility group box I (HMGB1) release from tumor cells after treatment: implications for development of targeted chemoimmunotherapy.  Journal of Immunotherapy.  2007 Sep;30(6):596-606.
  
• Atkins MB, Carbone D, Coukos G, Dhodapkar M, Ernstoff MS, Finke J, Gajewski TF, Gollob J, Lotze MT, Storkus W, Weiner LM.  Report on the ISBTC mini-symposium on biologic effects of targeted therapeutics.  Journal of Immunotherapy.  2007 Sep;30(6):577-90.  Review.
  

CONTACT INFORMATION

Dr. Michael T. Lotze
Phone: (412) 624-9375
Email: lotzemt@upmc.edu